P2‐505: Oral vaccine using viral vectors for Alzheimer's disease: PIB/PET studies in old cynomolgus monkeys | Zendy

Tabira Takeshi | Zendy; Matsumoto Shinei | Zendy; Tsukada Hideo | Zendy; Nakamura Shinichiro | Zendy; Hatano Kentaro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

P2‐505: Oral vaccine using viral vectors for Alzheimer's disease: PIB/PET studies in old cynomolgus monkeys

Author(s) -

Tabira Takeshi,

Matsumoto Shinei,

Tsukada Hideo,

Nakamura Shinichiro,

Hatano Kentaro

Publication year - 2011

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2011.05.1376

Subject(s) - medicine , saline , pathology , virology

dissolved in phosphate-buffered saline strongly evokes the antibody response to phage particles. 2) This response was dependent on MyD88 signaling. 3) A few copies of Abeta42 fibril mimotope-displaying phage clone induce anti-Abeta42 conformer antibody response in C57BL/6 and J20 mice Conclusions: B6-phage may provide a promising vaccination strategy for immunotherapy of Alzheimer’s diseasewithout the involvement of Abeta42-specific T cell immunity since the safety of bacteriophage for human has been investigated in a number of studies of phage therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research